With the huge growth in the generic drug market, there is no doubt that generic companies (hey there!) are searching for drugs with a soon-to-be-expired label. To make their (your) work easy, we collected not just the drug names, but also included other information like yearly sales, treatment, ingredients, and the disease they cure which could help them (you) easily choose the drug most profitable to develop a generic version 4 years in advance.
So, without any delay, here is the list of drug patents expiring in 2026. Thank us later!
The article has a list of drug patents in 2026. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
Drug Patent Expiration Report
Download the Drug Expiration Report 2026-2030 in pdf:
Avycaz
Ceftazidime / Avibactam
| Patents | Expiration Date |
|---|---|
| US7112592 | January 7, 2026 |
| US8471025 | August 12, 2031 |
| US9284314 | June 15, 2032 |
| US9695122 | June 15, 2032 |
| US8969566 | June 15, 2032 |
Dosage: Intravenous infusion
Company: Allergan
Ingredients: AVIBACTAM SODIUM; CEFTAZIDIME
Treatment: Intra-abdominal Infections, Urinary Tract Infections, and Pneumonia
Tavalisse
Fostamatinib
| Patents | Expiration Date |
|---|---|
| US8211889 | January 19, 2026 |
| US7538108 | March 28, 2026 |
| US7989448 | June 12, 2026 |
| US8163902 | June 17, 2026 |
| US7449458 | September 4, 2026 |
Dosage: Oral
Company: Rigel Pharmaceuticals
Ingredients: FOSTAMATINIB DISODIUM
Treatment: Chronic Immune Thrombocytopenia
Bridion
Sugammadex
| Patents | Expiration Date |
|---|---|
| USRE44733 | January 27, 2026 |
Dosage: Intravenous
Company: Merck & Co., Inc
Ingredients: SUGAMMADEX SODIUM
Treatment: Reversal of Neuromuscular Blockade Induced by Rocuronium
Briviact
Brivaracetam
| Patents | Expiration Date |
|---|---|
| US6911461 | February 21, 2026 |
Dosage: Oral, Intravenous
Company: UCB Group
Ingredients: BRIVARACETAM
Treatment: Partial-onset Seizures in People 1 month of age and older
Procoralan
Ivabradine
| Patents | Expiration Date |
|---|---|
| US7361650 | February 22, 2026 |
| US7361649 | February 22, 2026 |
| US7879842 | February 22, 2026 |
| US7867996 | December 12, 2026 |
Dosage: Oral
Company: Servier
Ingredients: IVABRADINE
Treatment: Symptomatic Management of Stable Heart-related Chest Pain and Heart Failure
Pradaxa
Dabigatran
| Patents | Expiration Date |
|---|---|
| US7932273 | March 7, 2026 |
Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: DABIGATRAN ETEXILATE MESYLATE
Treatment: Blood clots, Stroke
Ozempic
Semaglutide
| Patents | Expiration Date |
|---|---|
| US8536122 | March 20, 2026 |
| US8129343 | December 5, 2031 |
Dosage: Oral, Subcutaneous
Company: Novo Nordisk
Ingredients: SEMAGLUTIDE
Treatment: Type 2 Diabetes
Byetta
Exenatide
| Patents | Expiration Date |
|---|---|
| US6515117 | April 4, 2026 |
Dosage: Subcutaneous
Company: AstraZeneca
Ingredients: EXENATIDE SYNTHETIC
Treatment: Type 2 Diabetes
Rexulti
Brexpiprazole
| Patents | Expiration Date |
|---|---|
| US7888362 | April 12, 2026 |
| USRE48059 | December 23, 2028 |
Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: BREXPIPRAZOLE
Treatment: Schizophrenia, Major Depressive Disorder
Aveed
Nebido
| Patents | Expiration Date |
|---|---|
| US11179402 | April 14, 2026 |
| US10617696 | April 12, 2030 |
Dosage: Oral, Intramuscular injection
Company: Endo Pharmaceuticals
Ingredients: TESTOSTERONE UNDECANOATE
Treatment: Low Testosterone Levels in Men
Aptiom
Eslicarbazepine acetate
| Patents | Expiration Date |
|---|---|
| US9206135 | April 21, 2026 |
Dosage: Oral
Company: Sumitomo Pharma Co
Ingredients: ESLICARBAZEPINE ACETATE
Treatment: Partial-onset Seizures Epilepsy
Vocabria
Cabotegravir
| Patents | Expiration Date |
|---|---|
| US8410103 | April 28, 2026 |
| US10927129 | April 28, 2026 |
Dosage: Oral, Intramuscular Injection
Company: ViiV Healthcare
Ingredients: CABOTEGRAVIR
Treatment: HIV/AIDS
Jevtana
Cabazitaxel
| Patents | Expiration Date |
|---|---|
| US7241907 | June 10, 2026 |
Dosage: Intravenous
Company: Sanofi-aventis
Ingredients: CABAZITAXEL
Treatment: Metastatic Castration-resistant Prostate Cancer
Voltaren
Diclofenac
| Patents | Expiration Date |
|---|---|
| US8097651 | June 16, 2026 |
| US7759394 | June 16, 2026 |
Dosage: Oral, Rectal, Intramuscular, Intravenous, Topical
Company: GSK
Ingredients: DICLOFENAC POTASSIUM
Treatment: Inflammatory Diseases such as Gout
Trintellix
Vortioxetine
| Patents | Expiration Date |
|---|---|
| US7144884 | June 17, 2026 |
| US8722684 | June 30, 2031 |
Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: VORTIOXETINE HYDROBROMIDE
Treatment: Major Depressive Disorder
Zelboraf
Vemurafenib
| Patents | Expiration Date |
|---|---|
| US8143271 | June 21, 2026 |
| US7504509 | October 22, 2026 |
| US7863288 | June 20, 2029 |
| US8741920 | July 27, 2030 |
Dosage: Oral
Company: Genentech
Ingredients: VEMURAFENIB
Treatment: Late-stage Melanoma
Rhopressa
Netarsudil
| Patents | Expiration Date |
|---|---|
| US8450344 | July 11, 2026 |
| US9096569 | July 11, 2026 |
| US10174017 | January 27, 2030 |
| US10654844 | January 27, 2030 |
| US8394826 | November 10, 2030 |
| US9931336 | March 14, 2034 |
| US10588901 | March 14, 2034 |
| US9415043 | March 14, 2034 |
Dosage: Eye drops, Topical
Company: Aerie Pharmaceuticals
Ingredients: NETARSUDIL MESYLATE
Treatment: Glaucoma
Gilotrif
Afatinib
| Patents | Expiration Date |
|---|---|
| USRE43431 | July 13, 2026 |
| US8426586 | April 10, 2030 |
Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: AFATINIB DIMALEATE
Treatment: Non-small Cell Lung Carcinoma
Beleodaq
Belinostat
| Patents | Expiration Date |
|---|---|
| US6888027 | August 10, 2026 |
Dosage: Intravenous
Company: Acrotech Biopharma LLC
Ingredients: BELINOSTAT
Treatment: Hematological Malignancies and Solid Tumors
Cometriq
Cabozantinib
| Patents | Expiration Date |
|---|---|
| US7579473 | August 14, 2026 |
| US11091439 | January 15, 2030 |
| US8877776 | October 8, 2030 |
Dosage: Oral
Company: Exelixis, Inc
Ingredients: CABOZANTINIB S-MALATE
Treatment: Medullary Thyroid Cancer, Renal Cell Carcinoma, and Hepatocellular Carcinoma
Isturisa
Osilodrostat
| Patents | Expiration Date |
|---|---|
| US8835646 | August 23, 2026 |
| US8314097 | March 27, 2029 |
| US9434754 | January 13, 2031 |
Dosage: Oral
Company: Recordati Rare Diseases Inc
Ingredients: OSILODROSTAT PHOSPHATE
Treatment: Cushing’s Disease
Samsca
Tolvaptan
| Patents | Expiration Date |
|---|---|
| US8501730 | September 1, 2026 |
Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: TOLVAPTAN
Treatment: Hyponatremia
Sprycel
Dasatinib
| Patents | Expiration Date |
|---|---|
| US7491725 | September 28, 2026 |
Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: DASATINIB
Treatment: Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia
Aklief
Trifarotene
| Patents | Expiration Date |
|---|---|
| US7807708 | October 1, 2026 |
Dosage: Topical
Company: Galderma Laboratories
Ingredients: TRIFAROTENE
Treatment: Acne Vulgaris
Symproic
Naldemedine
| Patents | Expiration Date |
|---|---|
| USRE46375 | October 5, 2026 |
| USRE46365 | January 11, 2028 |
| US9108975 | November 11, 2031 |
| US10952968 | May 13, 2033 |
Dosage: Oral
Company: Shionogi & Co
Ingredients: NALDEMEDINE TOSYLATE
Treatment: Opioid-induced Constipation
Saphris
Asenapine
| Patents | Expiration Date |
|---|---|
| US7741358 | October 6, 2026 |
| US8022228 | October 6, 2026 |
Dosage: Sublingual
Company: Merck Sharp & Dohme
Ingredients: ASENAPINE MALEATE
Treatment: Schizophrenia
Uptravi
Selexipag
| Patents | Expiration Date |
|---|---|
| US7205302 | October 31, 2026 |
| US8791122 | August 1, 2030 |
Dosage: Oral, intravenous
Company: Actelion Pharmaceuticals
Ingredients: SELEXIPAG
Treatment: Pulmonary Arterial Hypertension
Bevyxxa
Betrixaban
| Patents | Expiration Date |
|---|---|
| US7598276 | November 8, 2026 |
Dosage: Oral
Company: Portola Pharmaceuticals, Inc
Ingredients: BETRIXABAN
Treatment: Venous Thrombosis
Orkambi
Lumacaftor / Ivacaftor
| Patents | Expiration Date |
|---|---|
| US9216969 | November 8, 2026 |
| US10597384 | December 4, 2028 |
| US8507534 | September 20, 2030 |
Dosage: Oral
Company: Vertex Pharmaceuticals
Ingredients: IVACAFTOR; LUMACAFTOR
Treatment: Cystic Fibrosis
Eliquis
Apixaban
| Patents | Expiration Date |
|---|---|
| US6967208 | November 21, 2026 |
Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: APIXABAN
Treatment: Blood Clots
Calquence
Acalabrutinib
| Patents | Expiration Date |
|---|---|
| US7459554 | November 24, 2026 |
| US9290504 | July 11, 2032 |
| US9796721 | July 1, 2036 |
Dosage: Oral
Company: AstraZeneca
Ingredients: ACALABRUTINIB
Treatment: Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Sirturo
Bedaquiline
| Patents | Expiration Date |
|---|---|
| US7498343 | December 1, 2026 |
| US8546428 | March 19, 2029 |
Dosage: Oral
Company: Janssen Therapeutics
Ingredients: BEDAQUILINE FUMARATE
Treatment: Multi-drug-resistant Tuberculosis
Adempas
Riociguat
| Patents | Expiration Date |
|---|---|
| US7173037 | December 4, 2026 |
| US10662188 | February 18, 2034 |
| US11203593 | February 18, 2034 |
Dosage: Oral
Company: Bayer
Ingredients: RIOCIGUAT
Treatment: Pulmonary Hypertension
Moxatag
Amoxicillin
| Patents | Expiration Date |
|---|---|
| US8778924 | December 8, 2026 |
Dosage: Oral, intravenous
Company: Pragma Pharmaceuticals
Ingredients: AMOXICILLIN
Treatment: Bacterial Infections
Inrebic
Fedratinib
| Patents | Expiration Date |
|---|---|
| US7528143 | December 16, 2026 |
| US7825246 | December 16, 2026 |
Dosage: Oral
Company: Impact Biomedicines
Ingredients: FEDRATINIB HYDROCHLORIDE
Treatment: Myeloproliferative
Imbruvica
Ibrutinib
| Patents | Expiration Date |
|---|---|
| US8697711 | December 28, 2026 |
| US9181257 | December 28, 2026 |
| US8957079 | December 28, 2026 |
| US8735403 | December 28, 2026 |
| US7514444 | December 28, 2026 |
| US8008309 | November 13, 2027 |
| US10125140 | June 3, 2033 |
| US9725455 | June 3, 2033 |
| US10106548 | June 3, 2033 |
| US9296753 | October 30, 2033 |
Dosage: Oral
Company: Janssen Biotech
Ingredients: IBRUTINIB
Treatment: Chronic Lymphocytic Leukemia
Kalydeco
Ivacaftor
| Patents | Expiration Date |
|---|---|
| US8754224 | December 28, 2026 |
| US7495103 | May 20, 2027 |
Dosage: Oral
Company: Vertex Pharmaceuticals
Ingredients: IVACAFTOR
Treatment: Cystic Fibrosis
Conclusion
Don’t you like to be on top of things? Well, so do we. And so, we got our pharma team working round the clock finding drug patents that expire 8 years from now. Yes, we like to be avant-garde. So if you want to stay ahead too subscribe to us and get the latest updates on drug patents that are expiring in the coming years!
Authored By: Divya Goyal, Team Lead, Life Science Team.
